Developer docs
API playgroundTry for free, no card

Search company profiles

MagAssist

Full company profile

uuid0002dku

Namestring
MagAssist
Legal namestring
MagAssist
Company typeenum
Private
Founded yearint
2017
Descriptiontext

MagAssist (心擎医疗) is a Chinese medical device company founded in 2017 and headquartered in Suzhou, with additional offices in Shanghai and Beijing. The company develops mechanical circulatory support (MCS) devices for patients with severe heart failure, spanning an extracorporeal fully magnetically suspended artificial heart (MoyoAssist), a minimally invasive percutaneous ventricular assist device (NyokAssist-PVAD), a next-generation extracorporeal membrane oxygenation (ECMO) system, and a warm-blood organ transport platform. The underlying technology is built around a proprietary fully magnetically suspended rotor architecture, which eliminates mechanical contact in the pump to reduce hemolysis and thrombosis — a technical differentiator relative to older friction-based pump designs and a foundation that supports cross-product R&D synergies across the MCS portfolio.

The company targets tertiary and quaternary hospitals and specialized cardiovascular centers in China through a direct institutional sales motion, with field teams operating from its three-city footprint. MagAssist is recognized as a unicorn enterprise and has appeared on the Future Healthcare 100 List for five consecutive years. The company has raised approximately $93 million across three funding rounds between 2019 and 2021, with investors including HSG, Cenova, CH Innovations, Northern Light Venture Capital, Med-Fine Capital, and Guoqian Venture Capital. International expansion signals include platform presentations at ISMCS 2025 in Vienna. Multiple products remain in development, and revenue is not publicly disclosed.

Revenue mechanics are anchored in hardware sales of life-supporting medical devices to healthcare institutions, with pricing negotiated directly through hospital procurement. The business model is concentrated in a single narrow customer segment — Chinese cardiac surgery and heart failure management departments — creating moderate concentration risk but also sticky, multi-year enterprise relationships once a device platform is adopted. The 51–100 person organization is structured to support parallel clinical, regulatory, and commercial functions across the four product platforms.

Short descriptiontext

MagAssist is a Chinese medical device company developing mechanical circulatory support platforms — including extracorporeal artificial hearts, percutaneous VADs, ECMO, and organ transport systems — for hospitals and cardiovascular centers treating severe heart failure.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSuzhou, China
HQ citystring
Suzhou
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
mechanical circulatory support, artificial heart devices, magnetic levitation pumps, extracorporeal membrane oxygenation, ventricular assist devices
Industry2 codes
PRIMARYHLAHAFAG
Mechanical Circulatory Support (VAD, IABP, ECMO)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Cardiovascular Medical Devices (Mechanical Circulatory Support)
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

MagAssist generates revenue through the sale of life-supporting medical devices including artificial hearts, ECMO systems, and organ transport platforms to hospitals and healthcare institutions. As a hardware-intensive medtech company, revenue is primarily derived from direct product sales to healthcare providers.

magassist.tech
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1MoyoAssist
Description

Extracorporeal fully magnetic levitation artificial heart product line.

magassist.tech
+1 more record
Core offering1 text field

MagAssist develops and manufactures mechanical circulatory support (MCS) medical devices centered on fully magnetically suspended rotor technology. Its current portfolio covers four platforms: MoyoAssist (extracorporeal full magnetic levitation artificial heart / VAD), NyokAssist-PVAD (minimally invasive interventional artificial heart / percutaneous ventricular assist device), a next-generation portable ECMO (extracorporeal membrane oxygenation) system, and a warm blood organ transport platform for transplant logistics. These devices are sold to hospitals and cardiovascular centers to support heart failure patients across bridge-to-recovery, bridge-to-transplant, destination therapy, acute cardiac/respiratory support, and organ preservation pathways.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Listed on the Future Healthcare 100 List for 5 consecutive years, indicating sustained recognition as a leading innovative medical device company in China.
Product overview1 text field

心擎医疗(MagAssist)从心衰领域出发,致力于构建多器官支持平台。公司产品组合 includes体外全磁悬浮人工心脏(MoyoAssist)、微创介入式人工心脏(NyokAssist-PVAD)、新一代体外膜肺氧合(ECMO)以及温血器官转运平台等,覆盖多种机械循环支持(MCS)应用场景。

Product and service4 records
1MoyoAssist (Extracorporeal Full Magnetic Levitation Artificial Heart)
CategoryVentricular Assist Devices (Mechanical Circulatory Support)
Description

Ventricular assist device providing temporary mechanical circulatory support using full magnetic levitation to eliminate mechanical contact in the blood path, reducing blood trauma and thrombosis risk for heart failure patients in tertiary/quaternary hospitals.

2NyokAssist-PVAD (Minimally Invasive Interventional Artificial Heart / pVAD)
CategoryPercutaneous Ventricular Assist Devices (Mechanical Circulatory Support)
Description

Percutaneous ventricular assist device (pVAD) designed for minimally invasive implantation, providing short-term mechanical cardiac support for patients with acute heart failure or undergoing high-risk cardiac procedures.

3ECMO (Next-Generation Extracorporeal Membrane Oxygenation System)
CategoryExtracorporeal Membrane Oxygenation (Life Support)
Description

Portable next-generation extracorporeal membrane oxygenation system providing combined cardiac and respiratory life support for patients with severe cardiopulmonary failure, including use cases outside traditional ICU settings.

4Warm Blood Organ Transport Platform
CategoryOrgan Preservation and Transport (Transplant Logistics)
Description

System for preserving and transporting donor organs in a warm, oxygenated, blood-perfused state during transit, intended to maintain organ viability and improve transplant logistics for hospitals and transplant programs.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Abbott
TypeBroad incumbent
Description

Global medtech leader behind HeartMate 3 LVAD and CentriMag/ECMO systems; the dominant incumbent MagAssist competes against in mechanical circulatory support, with a far deeper clinical evidence base and installed base.

TypeDirect peer
Description

Developer of the Impella percutaneous ventricular assist device family; the most direct global competitor to MagAssist's NyokAssist pVAD in the minimally invasive interventional VAD segment.

TypeBroad incumbent
Description

Major cardiovascular device incumbent with historical HVAD program and ECMO offerings; competes with MagAssist across multiple MCS categories with global commercial reach.

TypeDirect peer
Description

Japanese medtech with established ECMO systems and heart failure therapies; directly comparable as a multi-product MCS/heart failure player with a global footprint that MagAssist aspires to build.

TypeDirect peer
Description

Developer of extracorporeal ventricular assist devices (EXCOR) for pediatric and adult patients; the closest direct analog to MagAssist's MoyoAssist extracorporeal magnetic levitation artificial heart.

TypeDirect peer
Description

Manufacturer of the SynCardia Total Artificial Heart, a competing implantable mechanical circulatory support device; relevant peer as MagAssist extends toward permanent/destination therapy indications.

7CARMAT
TypeEmerging player
Description

French developer of a bioprosthetic total artificial heart; a thematic peer in next-generation mechanical heart replacement technology with similar long-horizon commercial and clinical challenges to MagAssist's artificial heart programs.

TypeEmerging player
Description

Hong Kong-based developer of bioartificial hearts and heart-in-a-jar technology; comparable emerging player with a focus on novel cardiac support platforms, though concentrated in preclinical/research tools rather than commercial MCS devices.

TypeEmerging player
Description

Developer of portable ECMO systems; directly comparable as a next-generation portable ECMO player competing with MagAssist's next-generation ECMO product.

TypeRegional player
Description

Chinese domestic competitor developing the CH-VAD implantable left ventricular assist device; the most direct Chinese medtech peer to MagAssist in the domestic MCS market, sharing similar regulatory pathway and customer base.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MagAssist

Cardiovascular Medical Devices (Mechanical Circulatory Support)magassist.com.cn

MagAssist is a Chinese medical device company developing mechanical circulatory support platforms — including extracorporeal artificial hearts, percutaneous VADs, ECMO, and organ transport systems — for hospitals and cardiovascular centers treating severe heart failure.

What MagAssist does

MagAssist (心擎医疗) is a Chinese medical device company founded in 2017 and headquartered in Suzhou, with additional offices in Shanghai and Beijing. The company develops mechanical circulatory support (MCS) devices for patients with severe heart failure, spanning an extracorporeal fully magnetically suspended artificial heart (MoyoAssist), a minimally invasive percutaneous ventricular assist device (NyokAssist-PVAD), a next-generation extracorporeal membrane oxygenation (ECMO) system, and a warm-blood organ transport platform. The underlying technology is built around a proprietary fully magnetically suspended rotor architecture, which eliminates mechanical contact in the pump to reduce hemolysis and thrombosis — a technical differentiator relative to older friction-based pump designs and a foundation that supports cross-product R&D synergies across the MCS portfolio.

The company targets tertiary and quaternary hospitals and specialized cardiovascular centers in China through a direct institutional sales motion, with field teams operating from its three-city footprint. MagAssist is recognized as a unicorn enterprise and has appeared on the Future Healthcare 100 List for five consecutive years. The company has raised approximately $93 million across three funding rounds between 2019 and 2021, with investors including HSG, Cenova, CH Innovations, Northern Light Venture Capital, Med-Fine Capital, and Guoqian Venture Capital. International expansion signals include platform presentations at ISMCS 2025 in Vienna. Multiple products remain in development, and revenue is not publicly disclosed.

Revenue mechanics are anchored in hardware sales of life-supporting medical devices to healthcare institutions, with pricing negotiated directly through hospital procurement. The business model is concentrated in a single narrow customer segment — Chinese cardiac surgery and heart failure management departments — creating moderate concentration risk but also sticky, multi-year enterprise relationships once a device platform is adopted. The 51–100 person organization is structured to support parallel clinical, regulatory, and commercial functions across the four product platforms.

MagAssist firmographics

Firmographics
Name
MagAssist
Legal name
MagAssist
Website
https://magassist.com.cn
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
MagAssist is a Chinese medical device company developing mechanical circulatory support platforms — including extracorporeal artificial hearts, percutaneous VADs, ECMO, and organ transport systems — for hospitals and cardiovascular centers treating severe heart failure.
Ownership category
akta.pro rank

MagAssist industry classification

Industry
Product category
Cardiovascular Medical Devices (Mechanical Circulatory Support)
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAFAG
Mechanical Circulatory Support (VAD, IABP, ECMO)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Mechanical circulatory support
  • Artificial heart devices
  • Magnetic levitation pumps
  • Extracorporeal membrane oxygenation
  • Ventricular assist devices

Where MagAssist is headquartered

Location

Headquarters

HQ city
Suzhou
HQ country
China
HQ region
Asia

Offices3 records

Markets served

MagAssist business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Medical Device Sales: MagAssist generates revenue through the sale of life-supporting medical devices including artificial hearts, ECMO systems, and organ transport platforms to hospitals and healthcare institutions. As a hardware-intensive medtech company, revenue is primarily derived from direct product sales to healthcare providers.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

MagAssist product offering

Product offering

Core offering

MagAssist develops and manufactures mechanical circulatory support (MCS) medical devices centered on fully magnetically suspended rotor technology. Its current portfolio covers four platforms: MoyoAssist (extracorporeal full magnetic levitation artificial heart / VAD), NyokAssist-PVAD (minimally invasive interventional artificial heart / percutaneous ventricular assist device), a next-generation portable ECMO (extracorporeal membrane oxygenation) system, and a warm blood organ transport platform for transplant logistics. These devices are sold to hospitals and cardiovascular centers to support heart failure patients across bridge-to-recovery, bridge-to-transplant, destination therapy, acute cardiac/respiratory support, and organ preservation pathways.

Product overview

心擎医疗(MagAssist)从心衰领域出发,致力于构建多器官支持平台。公司产品组合 includes体外全磁悬浮人工心脏(MoyoAssist)、微创介入式人工心脏(NyokAssist-PVAD)、新一代体外膜肺氧合(ECMO)以及温血器官转运平台等,覆盖多种机械循环支持(MCS)应用场景。

Differentiator

Problem solved

Functional benefit

Brands

  • MoyoAssist: Extracorporeal fully magnetic levitation artificial heart product line.
  • NyokAssist

Products and services

  • MoyoAssist (Extracorporeal Full Magnetic Levitation Artificial Heart) Ventricular assist device providing temporary mechanical circulatory support using full magnetic levitation to eliminate mechanical contact in the blood path, reducing blood trauma and thrombosis risk for heart failure patients in tertiary/quaternary hospitals.
  • NyokAssist-PVAD (Minimally Invasive Interventional Artificial Heart / pVAD) Percutaneous ventricular assist device (pVAD) designed for minimally invasive implantation, providing short-term mechanical cardiac support for patients with acute heart failure or undergoing high-risk cardiac procedures.
  • ECMO (Next-Generation Extracorporeal Membrane Oxygenation System) Portable next-generation extracorporeal membrane oxygenation system providing combined cardiac and respiratory life support for patients with severe cardiopulmonary failure, including use cases outside traditional ICU settings.
  • Warm Blood Organ Transport Platform System for preserving and transporting donor organs in a warm, oxygenated, blood-perfused state during transit, intended to maintain organ viability and improve transplant logistics for hospitals and transplant programs.

Quantifiable outcome

  • Listed on the Future Healthcare 100 List for 5 consecutive years, indicating sustained recognition as a leading innovative medical device company in China.

Companies that use MagAssist

Customer profile

Segments1 record

Ideal customer profiles1 record

MagAssist technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

MagAssist partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

MagAssist competitors and assessment

Company assessment

Broad incumbents

  • Abbott: Global medtech leader behind HeartMate 3 LVAD and CentriMag/ECMO systems; the dominant incumbent MagAssist competes against in mechanical circulatory support, with a far deeper clinical evidence base and installed base.
  • Medtronic: Major cardiovascular device incumbent with historical HVAD program and ECMO offerings; competes with MagAssist across multiple MCS categories with global commercial reach.

Direct peers

  • Abiomed (Johnson & Johnson MedTech): Developer of the Impella percutaneous ventricular assist device family; the most direct global competitor to MagAssist's NyokAssist pVAD in the minimally invasive interventional VAD segment.
  • Terumo: Japanese medtech with established ECMO systems and heart failure therapies; directly comparable as a multi-product MCS/heart failure player with a global footprint that MagAssist aspires to build.
  • Berlin Heart: Developer of extracorporeal ventricular assist devices (EXCOR) for pediatric and adult patients; the closest direct analog to MagAssist's MoyoAssist extracorporeal magnetic levitation artificial heart.
  • SynCardia Systems: Manufacturer of the SynCardia Total Artificial Heart, a competing implantable mechanical circulatory support device; relevant peer as MagAssist extends toward permanent/destination therapy indications.

Emerging players

  • CARMAT: French developer of a bioprosthetic total artificial heart; a thematic peer in next-generation mechanical heart replacement technology with similar long-horizon commercial and clinical challenges to MagAssist's artificial heart programs.
  • Novoheart: Hong Kong-based developer of bioartificial hearts and heart-in-a-jar technology; comparable emerging player with a focus on novel cardiac support platforms, though concentrated in preclinical/research tools rather than commercial MCS devices.
  • Breethe (alung technologies): Developer of portable ECMO systems; directly comparable as a next-generation portable ECMO player competing with MagAssist's next-generation ECMO product.

Regional players

  • CH Biomedical (苏州同心医疗器械): Chinese domestic competitor developing the CH-VAD implantable left ventricular assist device; the most direct Chinese medtech peer to MagAssist in the domestic MCS market, sharing similar regulatory pathway and customer base.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

MagAssist social profiles

Digital presence

MagAssist financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MagAssist leadership team

Management profile

Number of profiles

Profiles2 records

MagAssist funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MagAssist M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MagAssist

What does MagAssist do?

MagAssist develops and manufactures mechanical circulatory support (MCS) medical devices centered on fully magnetically suspended rotor technology. Its current portfolio covers four platforms: MoyoAssist (extracorporeal full magnetic levitation artificial heart / VAD), NyokAssist-PVAD (minimally invasive interventional artificial heart / percutaneous ventricular assist device), a next-generation portable ECMO (extracorporeal membrane oxygenation) system, and a warm blood organ transport platform for transplant logistics. These devices are sold to hospitals and cardiovascular centers to support heart failure patients across bridge-to-recovery, bridge-to-transplant, destination therapy, acute cardiac/respiratory support, and organ preservation pathways.

Is MagAssist a public or private company?

MagAssist is a private company. It is classified as venture growth investor backed and is currently operating.

When was MagAssist founded?

MagAssist was founded in 2017. It employs 11 to 50 people.

Where is MagAssist based?

MagAssist is headquartered in Suzhou, China, in the Asia region.

How does MagAssist make money?

One revenue line is on record: medical Device Sales.

Who are MagAssist's main competitors?

Broad incumbents on record are Abbott and Medtronic. Direct peers are Abiomed (Johnson & Johnson MedTech), Terumo, Berlin Heart and SynCardia Systems. Emerging players are CARMAT, Novoheart and Breethe (alung technologies). CH Biomedical (苏州同心医疗器械) is listed as a regional player.

Does MagAssist have an API?

No public API is recorded for MagAssist.

What industry is MagAssist in?

MagAssist's product category is Cardiovascular Medical Devices (Mechanical Circulatory Support). Its primary akta.pro industry code is HLAHAFAG, Mechanical Circulatory Support (VAD, IABP, ECMO), with a secondary code of HLAHAFAL, Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comKey Factors and Emerging Trends Shaping the Cardiac Assist Devices and Equipment Market LandscapeThe cardiac assist devices and equipment market is projected to grow to $3.76 billion by 2030, with a compound annual growth rate of 10.4%, driven by technological advances and increasing clinical applications. In June 2023, German cardiovascular device manufacturer Translumina acquired Netherlands-based Blue Medical Devices to incorporate its drug application technology into Translumina's product range. In September 2023, China-based magAssist received U.S. FDA Breakthrough Device designation for its NyokAssist interventional ventricular assist device following successful first-in-human use.PR NewswireFirst Patient with NyokAssist™ Interventional Ventricular Assist Device: Dr. Junbo Ge's team successfully completed the first high-risk PCI treatment supported by the new generation of interventionalDr. Junbo Ge's team at Zhongshan Hospital in Shanghai successfully completed the first-in-man use of NyokAssist™, an interventional ventricular assist device, supporting a high-risk PCI procedure on a 48-year-old male patient with complex coronary artery disease, heart failure, and diabetes. The procedure went well with the device providing circulatory support at 3.0 L/min, and the patient recovered successfully, being discharged just 2 days later. MagAssist Co., Ltd., the device developer, noted this as a milestone confirming the safety and effectiveness of NyokAssist™, which has also received FDA Breakthrough Device Program designation.PR NewswiremagAssist's NyokAssist™️ granted Designation by the FDA as a Breakthrough DevicemagAssist's NyokAssist™ Interventional Ventricular Assist Device has been granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA). This recognition highlights the device's innovative 9Fr insertion size and foldable catheter pump design, which aim to reduce vascular complications and improve hydraulic efficiency for high-risk percutaneous interventions.PR NewswireMedtech Innovator magAssist Inc. Gains Recognition for Its Innovation in the Cardiovascular Field at 2022 Critical Heart Disease Congress-International Society for Mechanical Circulatory Support ParalmagAssist Inc. attended the 2022 Critical Heart Disease Congress organized by the International Society for Mechanical Circulatory Support, where the company presented its BreathMoAssist™ portable ECMO system and clinical trial results for the MoyoAssist® Extra-VAD developed jointly with Wuhan Union Hospital. The MoyoAssist® Extra-VAD achieved a 94.5% patient survival rate across 37 patients enrolled at 12 medical centers in China. The company highlighted significant clinical demand for Chinese-made ECMO devices as a market opportunity, with plans to continue developing portable and intelligent cardiovascular treatment solutions.ForbesFour Innovative Small Businesses Driving ChangeFour start-ups—GoKwik, magAssist, Kargo, and Homage—were recognized for using technology to improve lives, with GoKwik winning the top FedEx Asia Pacific Small Business Grant prize of US$30,000. The others received US$13,000 each. GoKwik plans global expansion over five years.